Skip to main content

Phase 2, Randomized, Open-Label Study comparing Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) Versus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Subjects with Newly Diagnosed Multiple Myeloma Eligible for High dose chemo

Clinical Trial Grant
Duke Scholars

Administered By

Duke Cancer Institute

Awarded By

Janssen Research & Development, LLC

Start Date

October 11, 2017

End Date

June 30, 2022
 

Administered By

Duke Cancer Institute

Awarded By

Janssen Research & Development, LLC

Start Date

October 11, 2017

End Date

June 30, 2022